Treatment of a complex orthopaedic infection due to extensively drug-resistant Pseudomonas aeruginosa

Sidra Hassan, Mani D. Kahn, Nidhi Saraiya, Priya Nori

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

According to the Centers for Disease Control and Prevention (CDC), approximately 51 000 healthcare-associated infections caused by Pseudomonas aeruginosa occur annually in the USA, more than 6000 of which (13%) are caused by multidrug resistant (MDR) strains. Ceftolozane/tazobactam (TOL/TAZ) (Zerbaxa) was approved by the US Food and Drug Administration (FDA) in December 2014 for the treatment of complicated intra-abdominal and urinary tract infections. At this time, clinical data on the role of TOL/TAZ treatment outside of FDA-approved indications is limited. Herein, we present a case of extensively drug-resistant (XDR) P. aeruginosa osteomyelitis of the upper extremity, which was successfully treated with TOL/TAZ for 8 weeks with optimal clinical and laboratory responses. Monotherapy with TOL/TAZ appears effective for treatment of complicated bone and joint infections with XDR P. aeruginosa in combination with comprehensive surgical management, particularly when few antibiotic options exist.

Original languageEnglish (US)
JournalBMJ Case Reports
Volume2018
DOIs
StatePublished - Jan 5 2018

Keywords

  • drugs: infectious diseases
  • infections
  • musculoskeletal and joint disorders
  • skin

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Treatment of a complex orthopaedic infection due to extensively drug-resistant Pseudomonas aeruginosa'. Together they form a unique fingerprint.

  • Cite this